EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model

William S Lawrence iD, Jennifer E Peel, Richard A Slayden, Johnny W Peterson, Wallace B Baze, Martha E Hensel iD, Elbert B Whorton, David W C Beasley iD, Jason E Cummings, Ines Macias-Perez

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00112-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von William S Lawrence und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Lipoglycopeptides, Anthrax, Bacillus anthracis, Anti-Bacterial Agents. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhalation anthrax is the most severe form of Bacillus anthracis infection, often progressing to fatal conditions if left untreated. While recommended antibiotics can effectively treat anthrax when promptly administered, strains engineered for antibiotic resistance could render these drugs ineffective. Telavancin, a semisynthetic lipoglycopeptide antibiotic, was evaluated in this study as a novel therapeutic against anthrax disease. Specifically, the aims were to (i) assess in vitro potency of telavancin against 17 B. anthracis isolates by minimum inhibitory concentration (MIC) testing and (ii) evaluate protective efficacy in rabbits infected with a lethal dose of aerosolized anthrax spores and treated with human-equivalent intravenous telavancin doses (30 mg/kg every 12 hours) for 5 days post-antigen detection versus a humanized dose of levofloxacin and vehicle control. Blood samples were collected at various times post-infection to assess the level of bacteremia and antibody production, and tissues were collected to determine bacterial load. The animals’ body temperatures were also recorded. Telavancin demonstrated potent bactericidal activity against all strains tested (MICs 0.06–0.125 μg/mL). Further, telavancin conveyed 100% survival in this model and cleared B. anthracis from the bloodstream and organ tissues more effectively than a humanized dose of levofloxacin. Collectively, the low MICs against all strains tested and rapid bactericidal in vivo activity demonstrate that telavancin has the potential to be an effective alternative for the treatment or prophylaxis of anthrax infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipoglycopeptidesAnthraxBacillus anthracisAnti-Bacterial AgentsMicrobial Sensitivity TestsAminoglycosidesRespiratory Tract InfectionsAnimalsRabbitsDisease Models, AnimalLevofloxacinFemale

Stichwörter der Autor:innen

Bacillus anthracisantibioticinhalation anthraxrabbit modeltherapeutic

Substanzen

LipoglycopeptidestelavancinAnti-Bacterial AgentsAminoglycosidesLevofloxacin

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, Colorado, USA.
  • Department of Comparative Medicine and Research, University of Texas MD Anderson, Bastrop, Texas, USA.
  • Department of Epidemiology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Product Development Division, Cumberland Pharmaceuticals, Nashville, Tennessee, USA.

ORCID-Profile: William S Lawrence, Martha E Hensel, David W C Beasley

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Lawrence, W. S., Peel, J. E., Slayden, R. A., Peterson, J. W., Baze, W. B., Hensel, M. E., Whorton, E. B., Beasley, D. W. C., Cummings, J. E., & Macias-Perez, I. (2024). Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00112-24

Vancouver

Lawrence WS, Peel JE, Slayden RA, Peterson JW, Baze WB, Hensel ME, et al. Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00112-24

BibTeX
@article{Lawrence2024,
  author = {Lawrence, William S and Peel, Jennifer E and Slayden, Richard A and Peterson, Johnny W and Baze, Wallace B and Hensel, Martha E and Whorton, Elbert B and Beasley, David W C and Cummings, Jason E and Macias-Perez, Ines},
  title = {Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00112-24}
}
Kostenlos starten →